| Patent application number | Description | Published |
|---|
| 20110016585 | NOVEL DELTA9-ELONGASE FOR PRODUCTION OF POLYUNSATURATED FATTY ACID-ENRICHED OILS - The present disclosure relates to isolated polynucleotides encoding a delta 9-elongase, delta 9-elongases encoded by the isolated polynucleotides, expression vectors comprising the isolated polynucleotides, host cells comprising the expression vectors, and methods for producing delta 9-elongase and polyunsaturated fatty acids. | 01-20-2011 |
| 20150057346 | METHODS OF MAINTAINING INTRAMUSCULAR MYOGLOBIN LEVELS, MAINTAINING MAXIMAL AEROBIC CAPACITY, AND ENHANCING THE OXIDATIVE CAPACITY OF MUSCLE IN A SUBJECT - Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject in need thereof are provided. Generally, the methods include administering an effective amount of β-hydroxy-β-methylbutyrate to the subject. The β-hydroxy-β-methylbutyrate may be administered as part of a nutritional composition. | 02-26-2015 |
| 20150057350 | FIBROSIS BIOMARKERS AND METHODS OF USING SAME - Methods and systems for using fibrosis biomarkers associated with a prolonged period of physical inactivity are provided. Also provided is a method of reducing the effect of prolonged physical inactivity on the development of fibrosis in a subject who is experiencing or is expected to experience prolonged physical inactivity in the near future by administering a therapeutically effective amount of a leucine metabolite (e.g., β-hydroxy-β-methylbutyric acid (HMB)) to the subject. | 02-26-2015 |
| 20150250221 | SHELF-STABLE, CLEAR LIQUID NUTRITIONAL COMPOSITIONS COMPRISING EPIGALLOCATECHIN GALLATE (EGCG) AND METHODS FOR PREPARING THE SAME - Disclosed herein are shelf-stable, clear liquid nutritional compositions having a pH ranging from 2.5 to 4.6 and comprising water; at least one source of EGCg in an amount sufficient to provide 200-1700 mg/L of EGCg; and at least one source of protein in an amount sufficient to provide 25-45 g/L of total protein. The shelf-stable, clear liquid nutritional compositions lose no more than 20% by weight solids of the EGCg content present in the initial formulation of the compositions to epimerization, degradation, or both epimerization and degradation during heat sterilization. In certain embodiments, the loss of EGCg is exhibited by the amount of epimerization product GCg present in the shelf-stable, clear liquid nutritional composition following heat sterilization. Methods for preparing the shelf-stable, clear liquid nutritional compositions are also disclosed herein. | 09-10-2015 |
| 20150265650 | METHODS FOR ENHANCING THE EFFECT OF EGCG ON MITIGATING SKELETAL MUSCLE LOSS - Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate (“EGCg”) in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, thereby mitigating skeletal muscle loss in the subject. The combination of EGCg with zinc in a nutritional composition enhances the mitigating effect that EGCg has on muscle loss. Specifically, when used in combination, a nutritional composition containing both EGCg and zinc requires less EGCg to obtain the same mitigating effect that occurs in the same nutritional composition containing EGCg but no zinc. | 09-24-2015 |
| 20160022617 | TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH PROLONGED PHYSICAL INACTIVITY - Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future. | 01-28-2016 |
| 20160038457 | METHODS OF MAINTAINING AND IMPROVING MUSCLE FUNCTION - Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition. | 02-11-2016 |
| 20160066610 | METHODS FOR ENHANCING AGED MUSCLE REGENERATION - Compositions and methods for enhancing the regenerative capacity of an individual are provided. The compositions include, and the methods provide, a combination of an effective amount of epigallocatechin-3-gallate (EGCg) and an effective amount of beta-hydroxy-beta-methylbutyrate (HMB) to decrease the level of intramuscular FGF2, to enhance the regenerative capacity of muscle, or both. | 03-10-2016 |
